In B cells, 138 DEGs were shared by IREB2+ and IREB2+CD27+ cells (Figure 6E), and their signature predicted favorable prognosis in lung cancer and LUAD (Figure 6F), suggesting IREB2 may suppress malignancy within B cells. This evidence concerns the gene IREB2 and lung carcinoma.